Remarks

• Several other therapeutic options for patients with non-severe COVID-19 at highest risk of hospitalization are available: see decision support tool that displays benefits and harms of nirmatrelvir-ritonavir, molnupiravir, and remdesivir.
• The GDG considered in vitro data demonstrating that sotrovimab does not neutralize the currently circulating variants of SARSCoV-2 and their subvariants.
• There was consensus among the panel that the meaningful reduction of in vitro neutralization activity strongly suggests absence of clinical effectiveness of monoclonal antibodies such as sotrovimab.
• However, there was also consensus regarding the need for clinical trial evidence in order to confirm any clinical effectiveness of new monoclonal antibodies that reliably neutralize the circulating strains in vitro.